DOCSLIB.ORG

Comparative Safety and Effectiveness of Type 2 Diabetes Medicines Final Report September 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Safety and Effectiveness of Type 2 Diabetes Medicines Final Report September 2014 Type 2 Diabetes review – ToR 4 COMPARATIVE SAFETY AND EFFECTIVENESS OF TYPE 2 DIABETES MEDICINES FINAL REPORT SEPTEMBER 2014 A report by the Centre for Applied Health Economics (CAHE), Griffith University Type 2 Diabetes review – ToR 4 This report was commissioned by the Pharmaceutical Evaluation Branch, Department of Health, the Australian Government. Researchers: Erika Turkstra Senior research fellow, health technology assessment Martin Downes Research fellow, health technology assessment Emilie Bettington Senior research assistant Tracy Comans Senior research fellow, health technology assessment Paul Scuffham Professor and chair in health economics The assistance of Sanjeewa Kularatna with the data extraction and Gabor Mihala with the statistical analyses is appreciated. The advice provided by the Post-Market Review Section, Pharmaceutical Evaluation Branch, Department of Health and the Reference Group is also appreciated. Type 2 Diabetes review – ToR 4 CONTENTS ACRONYMS ............................................................................................................. III EXECUTIVE SUMMARY ............................................................................................ 1 PURPOSE OF THE REVIEW ........................................................................................... 1 BACKGROUND ............................................................................................................ 1 REVIEW OF CLINICAL GUIDELINES ................................................................................ 2 SYSTEMATIC LITERATURE REVIEW ................................................................................ 3 RESULTS ................................................................................................................... 4 CONCLUSION ........................................................................................................... 16 BACKGROUND ....................................................................................................... 18 SECTION A: REVIEW CLINICAL TREATMENT ALGORITHMS FOR TYPE 2 DIABETES ............................................................................................................... 20 A.1 AUSTRALIAN GUIDELINES ............................................................................... 21 A.1.1 RACGP and Diabetes Australia ..................................................................... 21 ''''''''''''' '''''''''''''''''''''''' '''''''''''''''''''''' '''''''''''''''' ........................................................................... 21 A.2 INTERNATIONAL GUIDELINES ........................................................................... 22 A.2.1 Canada .......................................................................................................... 23 A.2.2 England and Wales ........................................................................................ 23 A.2.3 New Zealand.................................................................................................. 26 A.2.4 United States of America ............................................................................... 26 A.3 SUMMARY OF CLINICAL GUIDELINES ................................................................ 27 SECTION B: LITERATURE REVIEW AND META-ANALYSES OF THE COMPARATIVE CLINICAL SAFETY AND EFFICACY OF TYPE 2 DIABETES MEDICATION ........................................................................................................... 29 B.1 METHODS FOR THE SYSTEMATIC LITERATURE REVIEW ..................................... 30 B.1.1 Stage 1: Identifying systematic reviews.......................................................... 30 B.1.2 Stage 2: Systematic literature review – update from identified reviews .......... 32 B.1.3 Stage 3: Identifying relevant RCTs ................................................................. 32 B.1.4 Stage 4: Identifying additional triple therapy trials .......................................... 33 B.1.5 Data extraction ............................................................................................... 34 B.1.6 Clinical outcomes included............................................................................. 34 B.1.7 Statistical analysis.......................................................................................... 34 B.2 RESULTS – MONOTHERAPY ............................................................................ 35 B.2.1 List of included trials - MONOTHERAPY ........................................................ 35 B.3 RESULTS – DUAL THERAPY ............................................................................ 38 B.3.1 List of included trials – DUAL THERAPY ....................................................... 38 B.3.2 Risk of bias – DUAL THERAPY ..................................................................... 41 B.3.3 Trial characteristics – DUAL THERAPY ......................................................... 42 B.3.4 Baseline characteristics – DUAL THERAPY .................................................. 42 B.3.5 Methods of analysis – DUAL THERAPY ........................................................ 42 B.3.6 Results – DUAL THERAPY ............................................................................ 42 B.3.7 Discussion – DUAL THERAPY ...................................................................... 43 B.4 RESULTS – TRIPLE THERAPY .......................................................................... 43 B.4.1 List of included trials – TRIPLE THERAPY .................................................... 43 B.4.2 Risk of bias – TRIPLE THERAPY .................................................................. 46 B.4.3 Trial characteristics – TRIPLE THERAPY ...................................................... 47 B.4.4 Baseline characteristics – TRIPLE THERAPY ............................................... 47 B.4.5 Methods of analysis – TRIPLE THERAPY ..................................................... 48 B.4.6 Results – TRIPLE THERAPY ......................................................................... 49 B.4.7 Discussion – TRIPLE THERAPY ................................................................... 63 B.5 RESULTS – THERAPY ADDED TO EXISTING MEDICATION .................................... 64 B.5.1 List of included trials – EXISITING MEDICATION .......................................... 64 B.5.2 Risk of bias – EXISTING MEDICATION ......................................................... 66 i Type 2 Diabetes review – ToR 4 B.5.3 Trial characteristics – EXISTING MEDICATION ............................................ 66 B.5.4 Baseline characteristics – EXISTING MEDICATION ...................................... 67 B.5.5 Methods of analysis – EXISTING MEDICATION ............................................ 67 B.5.6 Results – EXISTING MEDICATION ............................................................... 68 B.5.7 Discussion – EXISTING MEDICATION .......................................................... 74 SECTION C: SUMMARY AND DISCUSSION ............................................................ 75 REFERENCES ......................................................................................................... 78 ATTACHMENT TO SECTION B: SYSTEMATIC LITERATURE REVIEW ................... 85 B.1 METHODS ..................................................................................................... 85 B.1.1 Literature search for RCTs ............................................................................. 85 B.1.2 Full details of searches and terms .................................................................. 88 B.1.7 Statistical Analyses ........................................................................................ 91 B.3 RESULTS – DUAL THERAPY ............................................................................ 92 B.3.2 Assessment of bias – DUAL THERAPY ......................................................... 92 B.3.3 Trial characteristics – DUAL THERAPY ......................................................... 92 B.3.4 Baseline characteristics – DUAL THERAPY .................................................. 93 B.4 RESULTS – TRIPLE THERAPY .......................................................................... 94 B.4.2 Risk of bias – TRIPLE THERAPY .................................................................. 94 B.4.3 Trial characteristics – TRIPLE THERAPY ...................................................... 96 B.4.4 Baseline characteristics – TRIPLE THERAPY ............................................. 101 B.4.6 Results of the included trials – TRIPLE THERAPY ...................................... 106 B.5 RESULTS – THERAPY ADDED TO EXISTING MEDICATION .................................. 115 B.5.2 Risk of bias – EXISTING MEDICATION ....................................................... 115 B.5.3 Trial characteristics – EXISTING MEDICATION .......................................... 116 B.5.4 Baseline characteristics – EXISTING MEDICATION .................................... 119 B.5.6 Results of trials with a duration of less than one year – EXISTING MEDICATION ............................................................................................................. 120 ii Type 2 Diabetes review – ToR 4 ACRONYMS ACA = acarbose MI = myocardial infarction ACE = angiotensin converting enzyme Mor = mortality AE = adverse event MTC = mixed treatment comparison ALO = alogliptin MVD = microvascular disease Asp = aspart N = North bid = twice
Load more

Recommended publications
  • CDR Clinical Review Report for Soliqua
    CADTH COMMON DRUG REVIEW Clinical Review Report Insulin glargine and lixisenatide injection (Soliqua) (Sanofi-Aventis) Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin. Service Line: CADTH Common Drug Review Version: Final (with redactions) Publication Date: January 2019 Report Length: 118 Pages Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis
    Online Supplementary Content Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. doi:10.1001/jama.2016.9400. eMethods. Summary of Statistical Analysis eTable 1. Search Strategies eTable 2. Description of Included Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 3. Description of Included Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 4. Description of Included Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin Plus Sulfonylurea eTable 5. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 6. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 7. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin plus Sulfonylurea eTable 8. Estimated Global Inconsistency in Networks of Outcomes eTable 9. Estimated Heterogeneity in Networks eTable 10. Definitions of Treatment Failure Outcome eTable 11. Contributions of Direct Evidence to the Networks of Treatments eTable 12. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes Given as Monotherapy eTable 13. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes When Used in Dual Therapy (in Addition to Metformin) eTable 14. Network Meta-analysis Estimates of Comparative Treatment Effects for Drug Classes Given as Triple Therapy eTable 15. Meta-regression Analyses for Drug Classes Given as Monotherapy (Compared With Metformin) eTable 16. Subgroup Analyses of Individual Sulfonylurea Drugs (as Monotherapy) on Hypoglycemia eTable 17.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
    [Show full text]
  • Pharmaceuticals Compositions Comprising Sulphonylurea-Class Insulin Secretagogue and Polyethylene Glycol Castor Oil
    (19) & (11) EP 2 438 911 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.04.2012 Bulletin 2012/15 A61K 9/20 (2006.01) A61K 31/4439 (2006.01) A61K 31/64 (2006.01) A61K 9/16 (2006.01) (21) Application number: 10013440.2 (22) Date of filing: 08.10.2010 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hodzar, Damjan et al Designated Extension States: Lek Pharmaceuticals d.d. BA ME Verovskova 57 1526 Ljubljana (SI) (71) Applicant: LEK Pharmaceuticals d.d. 1526 Ljubljana (SI) (54) Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil (57) The present invention relates to the field of a rea-class insulin secretagogue active pharmaceutical in- pharmaceutical technology. More specifically, the gredient and at the same time, when both formulated into present invention relates to a pharmaceutical composi- a pharmaceutical composition, ensures satisfying or ex- tion comprising sulphonylurea-class insulin secreta- ceeding other parameters like for example stability, hard- gogue and a surface active agent. Surface active agent ness, friability and handling of said pharmaceutical com- obtainable by reacting castor oil or hydrogenated castor position. oil with ethylene oxide, preferably hydrogenated castor oil, substantially improves dissolution of the sulphonylu- EP 2 438 911 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 438 911 A1 Description Field of the invention 5 [0001] The present invention relates to the field of a pharmaceutical technology.
    [Show full text]
  • Curriculum Vitae
    David C. Klonoff MD, FACP, FRCP (Edin), Fellow AIMBE Page 1 CURRICULUM VITAE DAVID CHARLES KLONOFF, M.D., FACP, FRCP (Edin), FELLOW AIMBE Medical Director, Diabetes Research Institute, Mills-Peninsula Medical Center 100 South San Mateo Drive, Room 5147, San Mateo, California 94401 Phone 650-696-4260 / Fax 650-696-4269 [email protected] SUMMARY David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. He is the Founding Editor- in-Chief of Journal of Diabetes Science and Technology. He has authored over 270 publications in PubMed journals including four of the first ten articles on diabetes device cybersecurity.
    [Show full text]
  • Possible Role of Rivoglitazone Thiazolidine Class of Drug As Dual
    Medical Hypotheses 131 (2019) 109305 Contents lists available at ScienceDirect Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy Possible role of rivoglitazone thiazolidine class of drug as dual-target therapeutic agent for bacterial infections: An in silico study T ⁎ Vidyasrilekha Yele , Niladri Saha, Afzal Azam Md Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Ootacamund, JSS Academy of Higher Education & Research, Mysuru 643001, India ARTICLE INFO ABSTRACT Keywords: Infections due to resistant bacteria are the life-threatening and leading cause of mortality worldwide. The Rivoglitazone current therapy for bacterial infections includes treatment with various drugs and antibiotics. The misuse and ParE over usage of these antibiotics leads to bacterial resistance. There are several mechanisms by which bacteria MurE exhibit resistance to some antibiotics. These include drug inactivation or modification, elimination of antibiotics Docking through efflux pumps, drug target alteration, and modification of metabolic pathway. However, it is difficult to MM-GBSA treat infections caused by resistant bacteria by conventional existing therapy. In the present study binding af- Molecular dynamic simulations fi Anti-bacterial agent nities of some glitazones against ParE and MurE bacterial enzymes are investigated by in silico methods. As evident by extra-precision docking and binding free energy calculation (MM-GBSA) results, rivoglitazone ex- hibited higher binding affinity against both ParE and MurE enzymes compared to all other selected compounds. Further molecular dynamic (MD) simulations were performed to validate the stability of rivoglitazone/4MOT and rivoglitazone/4C13 complexes and to get insight into the binding mode of inhibitor. Thus, we hypothesize that structural modifications of the rivoglitazone scaffold can be useful for the development of an effective antibacterial agent.
    [Show full text]
  • Design, Synthesis, and Evaluation of Thiazolidinedione Derivatives Inhibiting Bcl-2/Bcl-Xl Or Ablating Androgen Receptor for the Treatment of Prostate Cancer
    DESIGN, SYNTHESIS, AND EVALUATION OF THIAZOLIDINEDIONE DERIVATIVES INHIBITING BCL-2/BCL-XL OR ABLATING ANDROGEN RECEPTOR FOR THE TREATMENT OF PROSTATE CANCER DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jian Yang, M.S. * * * * * The Ohio State University 2009 Dissertation Committee: Approved by Professor Ching-Shih Chen, Advisor Professor Pui-Kai (Tom) Li Adviser Professor Werner Tjarks Pharmacy Gradate Program Professor Dale Hoyt COPYRIGHT BY JIAN YANG 2009 ABSTRACT As of 2008, prostate cancer remains the number one cause of estimated new cancer cases in American men. Although early prostate cancer responds to androgen ablation, most tumors eventually recur as hormone-refractory prostate cancer (HRPC). Recent advances have identified many abnormal signaling pathways that contribute to the development of HRPC, mainly including dysregulation of androgen receptor (AR) function and the over- expression of the anti-apoptotic proteins, Bcl-2/Bcl-xL. It was found that thiazolidinediones (TZD), which include the anti-diabetic agents troglitazone, rosiglitazone, pioglitazone and ciglitazone, possess anti-tumor activity. It has been revealed that the anti-tumor activity of the TZDs could be attributed to PPARγ- independent mechanisms including Bcl-2/Bcl-xL inhibition and AR transcriptional repression. The objective of this dissertation is to further modify the TZD structures to enhance anti-prostate cancer activity by targeting the dysregulated Bcl-2/Bcl-xL and AR signaling pathways. Directed by method of molecular modeling, over 50 troglitazone derivatives have been designed and synthesized in two stages, yielding the optimal compound HepCNCF3, which showed two orders of magnitude improvement in Bcl-xL/Bcl-2 inhibition ii compared to troglitazone.
    [Show full text]
  • Canagliflozin, Dapagliflozin and Empagliflozin Monotherapy for Treating Type 2 Diabetes: Systematic Review and Economic Evaluation
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 21 ISSUE 2 JANUARY 2017 ISSN 1366-5278 Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt and Norman Waugh DOI 10.3310/hta21020 Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation Rhona Johnston,1 Olalekan Uthman,2 Ewen Cummins,1 Christine Clar,3 Pamela Royle,2 Jill Colquitt,4 Bee Kang Tan,2 Andrew Clegg,5 Saran Shantikumar,2 Rachel Court,2 J Paul O’Hare,2 David McGrane,6 Tim Holt7 and Norman Waugh2* 1McMDC, Harrogate, UK 2Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK 3Berlin, Germany 4Effective Evidence, Waterlooville, UK 5University of Central Lancashire, Preston, UK 6Queen Elizabeth University Hospital, Glasgow, UK 7University of Oxford, Oxford, UK *Corresponding author Declared competing interests of authors: David McGrane has spoken at educational meetings sponsored by AstraZeneca, Eli Lilly, Sanofi, MSD, Takeda Pharmaceutical Company, Novo Nordisk, Janssen, and has served on Advisory Boards for Eli Lilly, Sanofi, Novo Nordisk. J Paul O’Hare has received lecture fees, advisory board meeting fees, and grants for research from Novo Nordisk and Sanofi. All fees are paid through University of Warwick to fund access to insulin projects in sub-Saharan Africa. Published January 2017 DOI: 10.3310/hta21020 This report should be referenced as follows: Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,492.422 B2 Takahashi Et Al
    USOO9492422B2 (12) United States Patent (10) Patent No.: US 9,492.422 B2 Takahashi et al. (45) Date of Patent: Nov. 15, 2016 (54) THERAPEUTIC OR PROPHYLACTIC JP 52-136161 A 11/1977 AGENT FOR DIABETES JP 54-095552 A 7/1979 JP 54-130543. A 10, 1979 JP 55-000313 A 1, 1980 (75) Inventors: Takehiro Takahashi, Kamakura (JP); JP 55-022636 A 2, 1980 Hiroki Kumagai, Kamakura (JP); JP 55-057559 A 4f1980 JP 58-219 162 A 12/1983 Takashi Kadowaki, Tokyo (JP): Naoto JP 59-137445. A 8, 1984 Kubota, Tokyo (JP); Tetsuya Kubota, JP 59-141536 A 8, 1984 Tokyo (JP) JP 59-157050 A 9, 1984 JP 61-030519 A 2, 1986 (73) Assignees: Toray Industries, Inc. (JP); The JP 61-267580 A 11, 1986 JP 62-286924 A 12/1987 University of Tokyo (JP) JP 105.3672 B 11, 1989 JP 2-167227 A 6, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 3-005457 A 1, 1991 patent is extended or adjusted under 35 JP 3-246252 A 11, 1991 U.S.C. 154(b) by 36 days. JP 10-251.146 A 9, 1998 JP 2001-512478 A 8, 2001 JP 2006-199694 A 8, 2006 (21) Appl. No.: 13/509,483 JP 2006-523668 A 10, 2006 JP 2007-191494. A 8, 2007 (22) PCT Filed: Nov. 12, 2010 JP 2007-536229 A 12/2007 JP 2008-530097 A 8, 2008 (86). PCT No.: PCT/UP2010/070185 WO 99.1388.0 A1 3, 1999 WO OOO7992 A1 2, 2000 S 371 (c)(1), WO 02/088084 A1 11, 2002 (2), (4) Date: Jun.
    [Show full text]
  • 395 B 536 Winstal. O. Saito EEEEEE
    USOO8426439B2 (12) UnitedO States Patent (10) Patent No.: US 8.426,439 B2 Ciccocioppo (45) Date of Patent: *Apr. 23, 2013 (54) COMPOSITIONS AND METHODS FOR 7,510,728 B2 3/2009 Koike ........................... 424/464 PROPHYLAXIS AND TREATMENT OF 7,517,900 B2 4/2009 Pendri et al. ... 514,404 7,524,975 B2 4/2009 Mae et al. ... 549,405 ADDCTIONS 2002fOOO6942 A1 1/2002 Davis ........... ... 514,369 2002fOO77320 A1 6/2002 Lohray et al. 514/226.2 (75) Inventor: Roberto Ciccocioppo, Camerino (IT) 2003/0069246 A1 4/2003 Darrow et al. ................ 514,245 2003/010.0587 A1 5/2003 Moinet et al. ................. 514,369 (73) Assignee: Omeros Corporation, Seattle, WA (US) 2003/0220373 Al 1 1/2003 Jaye et al. ... 514,342 2004/0028735 A1 2/2004 Kositprapa ... 424/468 2004/OO77525 A1 4/2004 Chapman et al. ... 514/2 - r 2004/0096499 A1 5/2004 Vaya et al. ... 424/468 (*) Notice: Subject to any disclaimer, the term of this 2004/0127443 A1 7/2004 Pershadsingh 514,44 patent is extended or adjusted under 35 2004/0204472 A1 10/2004 Briggs et al. 514,406 U.S.C. 154(b) by 859 days. 2005, 00041 79 A1 1/2005 Pedersen ...... ... 514,342 2005, OO14786 A1 1/2005 Sun et al. .. ... 514/313 This patent is Subject to a terminal dis- 2005, OO 14833 A1 1/2005 Clark et al. .. ... 514,561 claimer. 2005, 0096331 A1 5/2005 Das et al. 514,259.3 2005, 01711.1.0 A1 8, 2005 Yu et al. ....... ... 514,248 2006, OOO9518 A1 1/2006 Campbell et al.
    [Show full text]
  • REVIEW Thyroid Hormone Receptors Regulate Adipogenesis And
    143 REVIEW Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors Changxue Lu and Sheue-Yann Cheng Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5128, Bethesda, Maryland 20892-4264, USA (Correspondence should be addressed to S-Y Cheng; Email: [email protected]) Abstract Peroxisome proliferator-activated receptors (PPARs) and thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily. They are ligand-dependent transcription factors that interact with their cognate hormone response elements in the promoters to regulate respective target gene expression to modulate cellular functions. While the transcription activity of each is regulated by their respective ligands, recent studies indicate that via multiple mechanisms PPARs and TRs crosstalk to affect diverse biological functions. Here, we review recent advances in the understanding of the molecular mechanisms and biological impact of crosstalk between these two important nuclear receptors, focusing on their roles in adipogenesis and carcinogenesis. Journal of Molecular Endocrinology (2010) 44, 143–154 Introduction (NR1C3; Fig. 1), are encoded by three different genes (PPARA, PPARD, and PPARG) located at chromosomes Peroxisome proliferator-activated receptors (PPARs) 22, 6, and 3 respectively. Upon ligand binding, PPARs and thyroid hormone receptors (TRs) are ligand- are recruited to peroxisome proliferator response dependent transcription receptors of the subfamily 1 elements (PPREs) in the regulatory region of target (NR1) in the nuclear receptor superfamily. The NR1 genes as heterodimers with the auxiliary factor RXR. group also includes retinoic acid receptors (RARs), With the PPAR/RXR heterodimers, either partner can Rev-erb, RAR-related orphan receptors (RORs), bind cognate ligands and elicit ligand-dependent oxysterol receptors (LXRs), vitamin D3 receptors transactivation (Kliewer et al.
    [Show full text]